• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience.

作者信息

Bomben Riccardo, Zucchetto Antonella, Laureana Roberta, Chiarenza Annalisa, Olivieri Jacopo, Tissino Erika, Rossi Francesca M, Vit Filippo, Bittolo Tamara, Papotti Robel, Pozzo Federico, Gaglio Annalisa, Degan Massimo, Polesel Jerry, Marasca Roberto, Visentin Andrea, Moia Riccardo, Innocenti Idanna, Vitale Candida, Murru Roberta, Varettoni Marzia, Tafuri Agostino, Zaja Francesco, Postorino Massimiliano, Martino Enrica A, Condoluci Adalgisa, Rossi Davide, Cuneo Antonio, Di Raimondo Francesco, Sportoletti Paolo, Del Giudice Ilaria, Foà Robin, Mauro Francesca R, Coscia Marta, Laurenti Luca, Gaidano Gianluca, Trentin Livio, Principe Maria I Del, Gentile Massimo, Gattei Valter

机构信息

Clinical and Experimental Onco-Haematology Unit Centro di Riferimento Oncologico di Aviano (CRO) IRCCS Aviano Italy.

Division of Haematology University of Tor Vergata Rome Italy.

出版信息

Hemasphere. 2024 Jul 15;8(7):e128. doi: 10.1002/hem3.128. eCollection 2024 Jul.

DOI:10.1002/hem3.128
PMID:39011128
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11247362/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0edb/11247362/22070d898925/HEM3-8-e128-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0edb/11247362/22070d898925/HEM3-8-e128-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0edb/11247362/22070d898925/HEM3-8-e128-g001.jpg

相似文献

1
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience.CD49d表达被纳入一个经过修订的四因素模型，该模型可预测接受依鲁替尼治疗的慢性淋巴细胞白血病患者的预后：一项多中心真实世界研究。
Hemasphere. 2024 Jul 15;8(7):e128. doi: 10.1002/hem3.128. eCollection 2024 Jul.
2
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.依鲁替尼治疗复发或难治性慢性淋巴细胞白血病患者的真实世界结果：来自一项同情用药项目中连续治疗的95例患者的数据。瑞典慢性淋巴细胞白血病研究组的一项研究。
Haematologica. 2016 Dec;101(12):1573-1580. doi: 10.3324/haematol.2016.144576. Epub 2016 May 19.
3
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.616 例美国伊布替尼治疗患者的毒性和结局：真实世界分析。
Haematologica. 2018 May;103(5):874-879. doi: 10.3324/haematol.2017.182907. Epub 2018 Feb 1.
4
Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.初治慢性淋巴细胞白血病患者开始一线应用伊布替尼或阿卡替尼的治疗时间。
Future Oncol. 2024 Jan;20(1):39-53. doi: 10.2217/fon-2023-0436. Epub 2023 Jul 21.
5
Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia.真实世界中接受伊布替尼治疗的慢性淋巴细胞白血病患者的依从性对临床结局的影响。
Leuk Lymphoma. 2022 Aug;63(8):1823-1830. doi: 10.1080/10428194.2022.2045597. Epub 2022 Mar 6.
6
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).西班牙接受伊布替尼单药治疗的慢性淋巴细胞白血病患者的真实世界特征和结局（IBRORS-LLC 研究）。
Clin Lymphoma Myeloma Leuk. 2021 Dec;21(12):e985-e999. doi: 10.1016/j.clml.2021.07.022. Epub 2021 Aug 3.
7
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.伊布替尼治疗慢性淋巴细胞白血病中 VLA-4（CD49d/CD29）的功能和临床相关性。
J Exp Med. 2018 Feb 5;215(2):681-697. doi: 10.1084/jem.20171288. Epub 2018 Jan 4.
8
Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.一线伊布替尼治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤的真实世界有效性结果数据的系统文献综述
Drugs Real World Outcomes. 2023 Mar;10(1):11-22. doi: 10.1007/s40801-022-00332-4. Epub 2022 Dec 19.
9
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.苯达莫司汀和利妥昔单抗在未经治疗的先前不适合的慢性淋巴细胞白血病患者中的疗效。在真实环境中与伊布替尼的间接比较。一项 GIMEMA-ERIC 和美国的研究。
Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.
10
Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.澳大利亚和新西兰慢性淋巴细胞白血病及套细胞淋巴瘤患者通过指定患者计划使用伊布替尼的真实世界经验。
Leuk Lymphoma. 2023 Feb;64(2):312-318. doi: 10.1080/10428194.2022.2148220. Epub 2022 Nov 24.

本文引用的文献

1
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.TP53 缺失对接受依鲁替尼治疗的慢性淋巴细胞白血病患者的临床影响：一项校园慢性淋巴细胞白血病研究
Leukemia. 2023 Apr;37(4):914-918. doi: 10.1038/s41375-023-01845-9. Epub 2023 Feb 18.
2
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.慢性淋巴细胞白血病：诊断与治疗程序的 2022 年更新。
Am J Hematol. 2021 Dec 1;96(12):1679-1705. doi: 10.1002/ajh.26367.
3
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.
伊布替尼治疗的 CLL 患者中核型复杂性和演变对生存的影响。
Blood. 2021 Dec 9;138(23):2372-2382. doi: 10.1182/blood.2020010536.
4
Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia.低变异等位基因频率的突变预示慢性淋巴细胞白血病患者生存期短。
Clin Cancer Res. 2021 Oct 15;27(20):5566-5575. doi: 10.1158/1078-0432.CCR-21-0701. Epub 2021 Jul 20.
5
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.TP53基因缺失作为靶向治疗时代的一个风险因素：一项对525例慢性淋巴细胞白血病病例的多中心回顾性研究。
Am J Hematol. 2021 Aug 1;96(8):E306-E310. doi: 10.1002/ajh.26235. Epub 2021 May 25.
6
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.4因素评分评估：对586例接受依鲁替尼治疗的慢性淋巴细胞白血病（CLL）患者的回顾性分析。一项校园CLL研究。
Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24.
7
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.伊布替尼治疗的慢性淋巴细胞白血病患者预后的预测：建立并验证一个四因素预后模型。
J Clin Oncol. 2021 Feb 20;39(6):576-585. doi: 10.1200/JCO.20.00979. Epub 2020 Oct 7.
8
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.CD49d 促进慢性淋巴细胞白血病的疾病进展：来自 CD49d 双模态表达的新见解。
Blood. 2020 Apr 9;135(15):1244-1254. doi: 10.1182/blood.2019003179.
9
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.接受伊布替尼治疗线和伊布替尼停药后慢性淋巴细胞白血病患者的结局：3 期分析。
Am J Hematol. 2019 May;94(5):554-562. doi: 10.1002/ajh.25436. Epub 2019 Mar 8.
10
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.iwCLL 指南：用于 CLL 的诊断、治疗指征、疗效评估和支持性管理。
Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.